# Junta clínica — PT-pseudo_a2ed5cd06259 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_a2ed5cd06259",
  "pid": "PT-pseudo_a2ed5cd06259",
  "task": 1,
  "psa": 4.6,
  "age": 76,
  "months": 3,
  "pirads": "5",
  "psad": 0.153,
  "psav": 0.81,
  "psap": 3.4,
  "vol": 30.02,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.8208632,
  "medhx": "Type 2 diabetes",
  "meds": "empagliflozin",
  "notes": "PSA 4.6 ng/mL. PI-RADS 5. PSAD 0.15. Prostate volume 30 mL. csPCa 0.82.",
  "pmhx": [
    "Type 2 diabetes"
  ],
  "allergies": [],
  "vitals": {
    "weight": "103 kg",
    "height": "193 cm",
    "bmi": "27.7",
    "bp": "137/83 mmHg",
    "hr": "65 bpm",
    "smoking": "Non-smoker",
    "last_dental": "3 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "10 Jan 2025",
  "enc_ref": "Dr. T. Hendriks (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Ascending PSA values combined with a previously positive biopsy require specialist re-evaluation."
    },
    {
      "s": "History",
      "t": "A 76-year-old non-smoker initially entered evaluation due to a late-2023 PSA elevation. Later, a systematic biopsy confirmed low-grade disease. Type 2 diabetes is managed using empagliflozin. An IPSS score of 2 points to negligible urinary symptom bother. Formerly a police officer, he is divorced and resides with his partner. Weekends feature hiking trips. Alcohol remains capped at 13 units weekly. Orthopaedic follow-ups address a chronic knee issue. Podiatry visits handle foot maintenance. An Arabic interpreter has been requested. Bone pain, haematuria, and unexplained weight loss are denied. Overall wellness stays steady."
    },
    {
      "s": "Physical examination",
      "t": "DRE: Texture is uniformly smooth. Dimensions are symmetric. No nodularity. No asymmetry. General inspection shows a well-nourished individual appearing comfortable. Vital signs remain stable. Cardiopulmonary assessment is normal."
    }
  ],
  "occupation": "retired police officer",
  "marital": "Divorced",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Orthopaedic outpatient — knee follow-up",
    "Podiatry — routine foot care"
  ],
  "alcohol": "13 units / week",
  "exercise": "Hiking on weekends",
  "ipss": "IPSS score: 2/35 (mild LUTS)",
  "admin": "Interpreter (Arabic) requested for next visit.",
  "mri_hospital": "Amsterdam UMC (location AMC)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_a2ed5cd06259
Task: 1

Encounter: Urology - outpatient on 10 Jan 2025.
Referrer: Dr. T. Hendriks (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 76-year-old male
  - PSA: 4.6 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.153 ng/mL²
  - PSA velocity: 0.81 ng/mL/yr
  - Prior PSA: 3.4 ng/mL
  - Prostate volume: 30.02 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8208632 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes
  - Problem list / PMHx: Type 2 diabetes
  - Current medication: empagliflozin
  - Allergies: NKA
  - Additional notes: PSA 4.6 ng/mL. PI-RADS 5. PSAD 0.15. Prostate volume 30 mL. csPCa 0.82.

Vitals: weight 103 kg, height 193 cm, BMI 27.7, BP 137/83 mmHg, HR 65 bpm. Smoking: Non-smoker.

Chief complaint: Ascending PSA values combined with a previously positive biopsy require specialist re-evaluation.

History: A 76-year-old non-smoker initially entered evaluation due to a late-2023 PSA elevation. Later, a systematic biopsy confirmed low-grade disease. Type 2 diabetes is managed using empagliflozin. An IPSS score of 2 points to negligible urinary symptom bother. Formerly a police officer, he is divorced and resides with his partner. Weekends feature hiking trips. Alcohol remains capped at 13 units weekly. Orthopaedic follow-ups address a chronic knee issue. Podiatry visits handle foot maintenance. An Arabic interpreter has been requested. Bone pain, haematuria, and unexplained weight loss are denied. Overall wellness stays steady.

Physical examination: DRE: Texture is uniformly smooth. Dimensions are symmetric. No nodularity. No asymmetry. General inspection shows a well-nourished individual appearing comfortable. Vital signs remain stable. Cardiopulmonary assessment is normal.

Patient info: retired police officer; Divorced; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 13 units / week; exercise Hiking on weekends; IPSS score: 2/35 (mild LUTS).

Recent other appointments: Orthopaedic outpatient — knee follow-up; Podiatry — routine foot care.
Admin: Interpreter (Arabic) requested for next visit.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.57
  uncertainty  +/- 0.10 epistemic (95% band 0.37-0.76); among patients I cannot tell apart the outcome was 0.99 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.94: PI-RADS 5, PSA 5.5, PSAD 0.12, age 71, DRE Normal -> BIOPSY (clear). He wrote: "Prev biopsy finding is left lobe, MRI finding highly suspicious of ISUP≥2 on right side. Active surveillance, only 1 biopsy session performed (of unclear date and unclea…"
  2. distance 1.15: PI-RADS 5, PSA 10.0, PSAD 0.27, age 75, DRE Normal -> BIOPSY (clear). He wrote: "New(? -> no old MRI report included) PIRADS 5 and rising PSA makes biopsy necessary"
  3. distance 1.31: PI-RADS 5, PSA 10.0, PSAD 0.372, age 75, DRE Normal -> BIOPSY (clear). He wrote: "Intermediate risk disease in 75yr with some comorbidity. No targeted biopsy and unclear timing (when was diagnosis and prev biopsy). Unclear if PIRADS5 was biopsied (lim…"

PRECEDENT: BIOPSY (weighted vote 1.00 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline discusses using the PI-RADS score and PSA density in relation to biopsy decisions. "linking PI-RADS score (1-2, 3, and 4-5) to PSA-D categories (< 0.10, 0.10-0.15, 0.15-0.20 and > 0.20ng/mL) (Table 5.5) [230]. This risk-adapted matrix table may guide the decision to perform a biopsy." This requires assessing the patient's PI-RADS score and PSA density against established risk-adapted matrices.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I disagree with the suggestion of biopsy because the guideline emphasizes risk-adapted matrices, which means the prior positive biopsy status is not sufficient to override the need for further assessment based on current imaging and lab values. EXPERT-LIBRARY, the precedents show that the decision is highly dependent on specific combinations of PI-RADS, PSA, and PSAD, which this patient's data alone does not satisfy.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the documented grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the rate of PSA change: a rising PSA velocity is a factor that must be considered in the risk assessment
laboratory_results - the PSA density: the PSA density value must be used in conjunction with the PI-RADS score for risk stratification

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on determining the documented grade of the prior biopsy and the surveillance plan detailed in the previous notes.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the lesion size or extraprostatic extension differ from an earlier study?
  psa_trend (get_psa_trend) -> What is the rate of PSA change, specifically the PSA velocity?
  previous_notes (get_previous_notes) -> What is the documented grade of the prior biopsy, and is there a surveillance protocol in place?
  laboratory_results (get_lab_results) -> What is the PSA density value, and how does it combine with the PI-RADS score for risk stratification?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade (Gleason or ISUP) of the prior biopsy?
  Q2. Is the patient currently on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: PI-RADS 5 lesion in the right anterior mid-gland.

psa_trend
What is the rate of PSA change, specifically the PSA velocity?
PSA velocity: 0.81 ng/mL/yr.

previous_notes
What is the documented grade of the prior biopsy, and is there a surveillance protocol in place?
The documented grade of the prior biopsy is not explicitly stated, and there is no surveillance protocol mentioned.

laboratory_results
What is the PSA density value, and how does it combine with the PI-RADS score for risk stratification?
The PSA density value is 0.153 ng/mL/mL, which combines with the PI-RADS 5 score for risk stratification.

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes provided the necessary information regarding the prior biopsy status and surveillance plan.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 lesion in the right anterior mid-gland, as per the radiology report.
Rising PSA velocity of 0.81 ng/mL/yr, as per the PSA trend.

AGAINST sampling this patient now
The documented grade of the prior biopsy is not explicitly stated, as per the previous notes.
No surveillance protocol is mentioned, as per the previous notes.

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 4.60 ng/mL over 5 points spanning 13 months; velocity +3.13 ng/mL per year; doubling time about 5 months.
PROJECTION at 6 months: 7.0 ng/mL, conformal 95% band 2.0-24.2.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.53
  uncertainty  +/- 0.10 epistemic (95% band 0.34-0.72), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.57  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.53  ('discuss' tier, fusion_full; weight 1.5)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=1.00  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.54 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('discuss' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.

Confidence the trace model expects here: borderline. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents retrieved by the registrar appear to have addressed the moderator's questions to the extent that they provided information, though not definitively answering both.

ALIGNMENT WITH THE PANEL
The panel protocol concluded with a 'BIOPSY' recommendation based on a weighted vote, but this decision rests on the fact that the documented prior grade was not recorded in the opened documents.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade (Gleason or ISUP) of the prior biopsy? This question remains unanswered as the previous notes stated the grade was not explicitly stated.
Q2. Is the patient currently on a surveillance protocol with a confirmatory biopsy due? This question remains unanswered as the previous notes stated no surveillance protocol was mentioned.

WHAT CARRIES WEIGHT, AND WHY
The documented grade of the prior biopsy is critical because the EAU guideline states that if the prior biopsy grade is ISUP 2 or above, treatment is indicated, not further tissue sampling. The surveillance status is also important as it dictates the urgency of the next step.

MY SUGGESTION TO THE CHAIR
Given that the critical information regarding the prior biopsy grade and surveillance status is missing from the retrieved documents, the decision cannot be definitively made according to the guideline's risk stratification.

VERDICT: not-ready | SUGGEST: defer | MISSING: previous_notes

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: borderline)

76y male, PSA 4.6, PSAD 0.153, PI-RADS 5, prior biopsy grade not recorded. High PI-RADS 5 and unrecorded prior grade suggest sampling for definitive diagnosis. Low PSA density argues for observation, but the new lesion warrants biopsy.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
